Vir Biotechnology Stock News

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK ) and Vir Biotechnology Inc (NASDAQ: VIR ) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence of viable SARS-CoV-2 in patients … Full story available on Benzinga.com

Vir Bio has a COVID blockbuster in Xevudy, and the stock is super-cheap right now.

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Baird has upgraded Vir Biotechnology <>, the partner of GlaxoSmithKline (GSK) in the development of COVID-19 therapy sotrovimab, to Neutral from Underperform, citing the recent…

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediat

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago q

Upgrades For Douglas Emmett Inc (NYSE: DEI ), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48, compared to year-ago quarter EPS of $0.40. At the moment, the stock has a 52-week-high of $36.97 and a 52-week-low of $29.38. Douglas Emmett closed at $32.18 at the end of the last trading period. According to Evercore ISI Group, the prior rating for Southwest Airlines Co (NYSE: LUV ) was changed from In-Line to Outperform. In the fourth quarter, Southwest Airlines showed an EPS of $0.14, compared to $1.29 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.75 and a 52-week-low of $38.66. Southwest Airlines closed at $42.32 at the end of the last trading period. According to DA Davidson, the prior rating for SciPlay Corp (NASDAQ: SCPL ) was changed from Neutral to Buy. SciPlay earned $0.09 in the fourth quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $22.29 and a 52-week-low of $10.75.

SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42nd Annual

SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the Company will participate in an infectious disease panel discussion at the 42 nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET. The conference will be held virtually. A live webcast … Full story available on Benzinga.com

Here are four stocks that ought to chase the bear away.

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

VIR vs. ILMN: Which Stock Is the Better Value Option?

Vir Biotechnology, Inc. (VIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst